What You Should Know:
– NVIDIA announced widespread adoption of its open-source BioNeMo™ Framework by pharmaceutical companies, techbio innovators, and AI researchers to accelerate drug discovery and molecule design.
– The framework provides a powerful suite of tools for scaling AI models in biomolecular research, bringing supercomputing capabilities to the forefront of drug development.
Accelerating Drug Discovery with AI
The BioNeMo Framework addresses the growing need for specialized tools to handle the complex demands of biomolecular research. By providing a collection of accelerated computing resources, it enables researchers to:
- Scale AI models: Exponentially increase the scale of AI models used in drug discovery.
- Gather insights at scale: Analyze vast datasets and extract meaningful insights more efficiently.
- Design therapeutics faster: Accelerate the process of designing and developing new drugs.
Introducing the Next-Generation BioNeMo Platform
The end-to-end NVIDIA BioNeMo platform is designed to streamline the entire AI drug discovery workflow, from model creation and customization to deployment. Key components of the platform include:
- BioNeMo Framework: Provides the foundation for building and scaling AI models.
- NVIDIA NIM™: Offers optimized microservices for secure and scalable AI inference.
- NVIDIA BioNeMo Blueprints: Provides optimized reference designs for wet-lab and computational workflows.
New NIM Microservices for Accelerated Drug Discovery
NVIDIA also announced new NIM microservices for BioNeMo, supporting industry-leading models like:
- AlphaFold2: Accelerates protein structure prediction.
- DiffDock 2.0: Improves the speed and accuracy of predicting molecular orientation.
- RFdiffusion and ProteinMPNN: Speed up the design of novel proteins for therapeutic applications.
BioNeMo Blueprints for Scalable AI Deployments
BioNeMo Blueprints offer customizable reference AI workflows, enabling developers to scale their AI deployments as enterprise-grade production pipelines. The BioNeMo Blueprint for virtual screening, for example, streamlines the process of designing small molecules.
Widespread Adoption and Industry Support
Over 200 organizations, including techbios, pharmaceutical companies, and startups, are already integrating BioNeMo into their drug discovery workflows. Global system integrators like Accenture, AWS, and Deloitte are also bringing BioNeMo Blueprints to enterprises worldwide.
“The convergence of AI, accelerated computing and expanding datasets offers unprecedented opportunities for the pharmaceutical industry, as evidenced by recent Nobel Prize wins in chemistry,” said Kimberly Powell, vice president of healthcare at NVIDIA. “To help unravel the complexities of biological systems, we’ve introduced the open-source BioNeMo Framework, which will enable researchers worldwide to accelerate the development of life-saving treatments.”
